ATAI ATAI LIFE SCIENCES BV

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences:

  • Financial Times Pharma and Biotech Summit in London

    Format: Industry Panel

    Date and Time: Wednesday, November 9th, 9:55 a.m. – 10:40 a.m. ET

    Conference link:
  • Credit Suisse Annual Healthcare Conference in Southern California

    Format: Fireside Chat

    Date and Time: Wednesday, November 9th, 4:35 p.m. – 6:35 p.m. ET

    Conference link:
  • HLTH in Las Vegas

    Format: Industry Panel

    Date and Time: Monday, November 14th, 7:20 p.m. - 8:00 p.m. ET

    Conference link:
  • Jefferies Healthcare Conference in London

    Format: Fireside Chat

    Date and Time: Wednesday, November 16th, 8:00 a.m. – 8:30 a.m. GMT

    Conference link:
  • Collaborating for Novel Solutions (CNS) Summit in Boca Raton, Florida

    Format: Keynote Industry Panel

    Date and Time: Saturday, November 19th, 12 p.m. – 12:30 p.m. ET

    Conference link:

Certain events will have archived webcasts available in the section of atai’s website at , where they will be available for up to 90 days.

About atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit

Contact Information

Investor Contact:

Stephen Bardin

Chief Financial Officer

Email:

Media Contact:

Allan Malievsky

Senior Director of External Affairs

Email:  



EN
01/11/2022

Underlying

ATAIATAI LIFE SCIENCES BV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthenin...

AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that the United States Patent and Trademark Office has granted a new patent covering EMP-01 (oral R-MDMA), further strengthening the company’s intellectual property estate and long-term...

December 11, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley to Participate in the Jefferies Global Healthcare Conferen...

AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Kevin Craig, M.D., Chief Medical Officer, are scheduled to participate in the Jefferies Global Healthcare Conference in London, UK. De...

November 13, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Co...

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights AtaiBeckley solidifies position as a global leader in transformative mental health therapies with a short psychedelic duration BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b open-label extension (OLE) study of BPL-003 showing the potential added and sustained antidepressant effects following a second dose in patients with TRD Repo...

November 12, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Lab...

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg ...

November 10, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences and Beckley Psytech Announce the Successful Complet...

atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies atai Life Sciences’ shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the Extraordinary General Meeting of Shareholders on November 4, 2025, with approximately 98% of the votes cast at the Extraordinary General Meeting in favor of the transactionsAtaiBeckley has an industry-leading pipeline of investigational treatments, led by BPL-003 (...

November 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch